W3C home > Mailing lists > Public > public-semweb-lifesci@w3.org > May 2011

Re: HCLS chartering/next steps Thur 26 May

From: Tim Clark <twclark@nmr.mgh.harvard.edu>
Date: Thu, 26 May 2011 11:55:37 -0400
Cc: HCLS IG <public-semweb-lifesci@w3.org>
Message-Id: <E44A239A-040C-4C7D-A266-94DD348ADC96@nmr.mgh.harvard.edu>
To: Michael Miller <Michael.Miller@systemsbiology.org>
HI Michael,

As I said, problem focused activities hiding in solution-focused groups.  The BioRDF group's very name is solution-focused.  Granted, over its recent history there has been a strong problem focus in the actual activities, I am thinking of the gene list work here.  But someone looking from the outside can't necessarily see that, they see "RDF" in the name.  

Best

Tim

On May 26, 2011, at 11:36 AM, Michael Miller wrote:

> hi all,
>  
> tim, your remarks confused me.  like lena, i have found BioRDF to be problem-centric.  the fact that we are working on solutions to the problem is what brings me to the table.  without that, BioRDF would be without me.
>  
> i stayed in the shadows for many years because i saw a lot of discussion and nothing that would help me in my day to day job.  that has changed in the last few years and has made me a more active member.  kudos to eric and lena, and many others, with their focus on making these technologies practical and accessible to solve problems, not just talk about them.
>  
> cheers,
> michael
>  
> From: public-semweb-lifesci-request@w3.org [mailto:public-semweb-lifesci-request@w3.org] On Behalf Of Helena Deus
> Sent: Thursday, May 26, 2011 7:45 AM
> To: Joanne Luciano
> Cc: Tim Clark; HCLS IG; Mikel Egaņa Aranguren
> Subject: Re: HCLS chartering/next steps Thur 26 May
>  
> Hi all,
>  
> I agree with a focus on creating "problem-centric" task forces - to be honest, I always felt bioRDF to be a problem-centered group (i.e. trying to solve a current problem in life sciences, not looking for a problem given a solution).
>  
> I do believe, however, that we need to make sure that we are all in the same page regarding goals. I propose that, for the next charter we agree on a Mission Statement devised and agreed upon by the key players in each task force. 
>  
> This will give us 1) focus;  2) requirements and 3) adequability of the task forces
> Cheers,
> Lena
>  
>  
> On Thu, May 26, 2011 at 3:33 PM, Joanne Luciano <jluciano@cs.rpi.edu> wrote:
> Tim,
>  
> Thanks for your thoughts. I agree with you and would like to add an evaluation criteria component - these efforts (imo) should be targeted at having an impact on clinical outcome.
>  
> Joanne
>  
> ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
> Joanne S. Luciano, PhD                            Rensselaer Polytechnic Institute 
> Research Associate Professor                 110 8th Street, Winslow 2143
> Tetherless World Constellation                Troy, NY 12180, USA 
> Department of Computer Science            Email: jluciano@cs.rpi.edu
> Office Tel. +1.518.276.4939                         Global Tel. +1.617.440.4364 (skypeIn)
>  
> On May 26, 2011, at 9:55 AM, Tim Clark wrote:
>  
> Dear HCLS colleagues
>  
> I guess my comment would be, setting Translational Medicine as a major priority = ok, making it the only priority = not ok.  
>  
> TM applications are important, and do potentially integrate many of the things we have all been working on. But they are far from covering all the bases, and far from covering all the use cases of critical concern to people in my Task Group, Scientific Discourse. 
>  
> I'll just observe that since we launched the multiple task groups we have ended up with two kinds of groups:  
>  
> (1) Problem Centric, e.g. TM and Scientific Discourse 
> (2) Solution Centric, e.g. LODD, BioRDF, Terminology
>  
> My personal recommendation would be to formulate the charter around accelerating biomedical research and promoting cross-discipline sharing, across the full scientific and clinical life cycle.  I would begin by dividing into several distinct problem focused areas. I would lose the solution-based Task Groups and reformulate them as problem-based.
>  
> for example, BioRDF has been working on gene lists for transcriptomic experiments, we might recharter that Task Group to work on Genomic Experiments, for example, or whatever concept area the Task members like and is a logical step from what they are doing now, but with a PROBLEM FOCUS ... you see the point. 
>  
> I think each of the solution centric groups has a potential problem centric group hiding inside it, waiting to come out.
>  
> Best
>  
> Tim
>  
> On May 26, 2011, at 9:31 AM, Helena Deus wrote:
> 
> 
> Hi,
> 
> That is a very good point, thanks Mikel and Andrea!
> Do you have pointers to such type of data? Shall we consider an IG for "basic" life sciences?
>  
> The LS part of HCLS has indeed been gaining adepts rapidly and it may make sense to reflect that in the charter. 
> 
> Cheers,
> Lena
>  
> 2011/5/26 Mikel Egaņa Aranguren <megana@fi.upm.es>
> Hi;
> 
> I should attend the conference call but I just want to add that I concur with Andrea in that the HCLS IG should consider the environmental realm, since loads of new ecological/environment data, with new challenges to be addressed, are waiting to be represented semantically. That's precisely one of the lines we are trying to open here at OEG-UPM.
> 
> Cheers
> 
> 
> On og., 2011.eko mairen 26a 15:08, Andrea Splendiani wrote:
> Hi,
> 
> I see myself as more involved in the next incarnation of the charter ;)
> Unfortunately, today is a travel day and I cannot attend the conference
> call.
> 
> I have two questions/ideas, which don't really map to the current
> sub-groups, but just in case they ring some bell:
> 
> -) Is the HCLS exclusively oriented on HeathCare ? (that is, is the "and" in
> Heath Care and Life Sciences IG and AND or an OR ?). Here in Rothamsted, we
> are just starting to evaluate the Ecological/Agricultural/Environmental
> connections to Life Sciences. Does this fall into the remit of the IG group
> ?
> 
> -) Does the evaluation/ coordination of development of systems which link
> information representation and analysis side fall within the remit of the IG
> ? I think interfaces to linked data, as well as tools which can analyze
> linked data are important to improve the acceptance of Semantic Web
> technologies in the Life Sciences.
> 
> ciao,
> Andrea
> 
> 
> 
> 
> Il giorno 24/mag/2011, alle ore 04.04, Eric Prud'hommeaux ha scritto:
> 
> Hi all, as some of you reallize, the charter ends at the end of this
> month. I've been polling around to see what alternative formulations
> would give us the most resources and impact. In the process, I wrote
> up some of our high-level use cases (elevator speeches) to help us
> approach the relevant parties in pharmas, health services and
> research:<http://www.w3.org/2011/05/HCLSIGUseCases>.
> 
> I'd like to discuss the landscape and potential strategies with the
> community. I'd particularly like to invite those who have been active
> or see themselves as being active in the next incarnation of the group.
> We'll discuss the current, fairly conservative draft charter
> <http://www.w3.org/2011/05/HCLSIGCharter-proposal>, as well as ways to
> optimize both its message and the paths for dissemination. An example
> of a messaging alternative would be to characterize the HCLS IG work
> in terms of e.g. overarching translational medicine use cases:
> "
>  The W3C Semantic Web in Health Care and Life Sciences Interest Group
>  focuses on translational medicine use cases. The group will continue
>  the aggregation of cutting edge and traditional scientific knowledge
>  to meet use cases for researchers, care givers, patients and
>  regulatory agencies. Due to the scope and diversity of expertise
>  required to meet translational needs, the HCLS IG work is broken
>  down into discrete task forces focused on particular data
>  acquisition, modeling and integration requirements:
> 
>  Terminology - identifying and integrating identifiers for biological
>  processes, gross anatomy and medical procedures to promote
>  unification of domain data.
> 
>  LODD - curation of compounds, clinical trials and outcomes.
> 
>  BioRDF - modeling of biological processes and actors.
> 
>  Scientific Discourse - representation and tracking of the changing
>  landscape of scientific knowledge and the driving theora and
>  experiments.
> 
>  Translational Medicine - the oversight and high-level ontology that
>  connects these disciplines together in order to meet immediate and
>  long term needs from pharma, health care and other vested parties.
> "
> . Perhaps you all have some other ideas about how to tell a story
> about our work which will serve to both draw people to our work and
> our products and to help already interested parties find the task
> forces which interest them. I of course want to draw an optimal
> balance between doing work which motivates the participants and
> focusing on tasks which will accelerate education and adoption by
> important organizations.
> 
> I'm sure you are all aware of my preference for technical work, but I
> feel that this outreach can make us all ultimately more effective. I
> will use the Thursday 26 May HCLS slot (11:00 EDT) to reach out to the
> current HCLS IG community, and whomever else you folks elect to bring
> along. Of course, I'll reserve extra teleconference slots, but please
> RSVP to me privately so I can make a guess at how many ports to
> reserve. Also, please provide what feedback you can before the
> conference. Anything we take care of before will make the meeting more
> efficient.
> 
> Conference Details
> 
> Date of Call: Thursday, May 26, 2011
> Time of Call: 11:00 am Eastern Time, 4 pm UK, 5 pm CET
> Dial-In #: +1.617.761.6200 (Cambridge, MA)
> [Note: limited access to European dial in numbers below]
> Dial-In #: +33.4.26.46.79.03 (Nice, France)
> Dial-In #: +44.203.318.0479 (Bristol, UK)
> Participant Access Code: 4257 ("HCLS")
> IRC Channel: irc.w3.org port 6665 channel #HCLS (see W3C IRC page for
> details, or see Web IRC), Quick Start: Use
> http://www.mibbit.com/chat/?server=irc.w3.org:6665&channel=%23hcls for
> IRC access.
> Duration: ~1 hour
> Convener: Eric Prud'hommeaux
> Scribe: TBD
> 
> HCLS IG charter/strategy discussion
> -- 
> -ericP
> 
> Andrea Splendiani
> Senior Bioinformatics Scientist
> Centre for Mathematical and Computational Biology
> +44(0)1582 763133 ext 2004
> andrea.splendiani@bbsrc.ac.uk
> 
> 
> 
> 
> 
>  
> -- 
> Mikel Egaņa Aranguren, PhD
> http://mikeleganaaranguren.com
> 
> Marie Curie post-doc at Ontology Engineering Group, UPM
> http://www.oeg-upm.net/
> 
> 
> 
> 
> 
> -- 
> Helena F. Deus
> Post-Doctoral Researcher at DERI/NUIG
> http://lenadeus.info/
>  
>  
> 
> 
> The information in this e-mail is intended only for the person to whom it is
> addressed. If you believe this e-mail was sent to you in error and the e-mail
> contains patient information, please contact the Partners Compliance HelpLine at
> http://www.partners.org/complianceline . If the e-mail was sent to you in error
> but does not contain patient information, please contact the sender and properly
> dispose of the e-mail.
>  
> ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
>  
> 
> 
> 
> -- 
> Helena F. Deus
> Post-Doctoral Researcher at DERI/NUIG
> http://lenadeus.info/
>  
Received on Thursday, 26 May 2011 15:56:11 GMT

This archive was generated by hypermail 2.3.1 : Tuesday, 26 March 2013 18:01:01 GMT